CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Radiation Response Modulation of GW572016 (EGFR/HER2 Dual Tyrosine Kinase Inhibitor) in Human Breast Cancer Xenografts
Yeon Sil Kim, Kwang Won Roh, Soo Min Chae, Seong Kwon Mun, Sei Chul Yoon, Hong Seok Jang, Su Mi Chung
Radiation Oncology Journal. 2007;25(4):233-241.

Excel Download

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance
International Journal of Radiation Oncology*Biology*Physics. 2004;58(2):344-352   Crossref logo
Link1 Link2

554 POSTER The mTOR effector p70 S6 kinase 1 (S6K1): a specific biomarker for the biological effects of the dual HER1/HER2 kinase inhibitor Lapatinib (GW572016) in HER2-overexpressing breast cancer cells
European Journal of Cancer Supplements. 2006;4(12):168   Crossref logo
Link1 Link2

194. Combining the Dual Tyrosine Kinase Inhibitor, Lapatinib, with HER2 Specific Cytotoxic T-Lymphocytes in the Treatment of HER2 Overexpressing Breast Cancer
Molecular Therapy. 2012;20:S77   Crossref logo
Link1 Link2

Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts
Cancer Chemotherapy and Pharmacology. 2007;61(2):179-188   Crossref logo
Link1 Link2 Link3

Dual HER-2/EGFR tyrosine kinase inhibitors
Breast Cancer Research. 2001;3(1):   Crossref logo
Link1 Link2 Link3

Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor
Clinical Breast Cancer. 2016;16(5):344-348   Crossref logo
Link1 Link2

Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates
Breast Cancer Research. 2000;2(3):   Crossref logo
Link1 Link2 Link3

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+breast cancer
Breast Cancer Research. 2009;11(S1):   Crossref logo
Link1 Link2 Link3

567 POSTER Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents
European Journal of Cancer Supplements. 2006;4(12):172   Crossref logo
Link1 Link2

Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts
European Journal of Cancer. 2002;38:S62   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Radiat Oncol J has participated in CrossRef Text and Data Mining service since October 29, 2014.